Journal article
IgG Antibody Responses Are Preferential Compared with IgM for Use as Serological Markers for Detecting Recent Exposure to Plasmodium vivax Infection
RJ Longley, MT White, J Brewster, ZSJ Liu, C Bourke, E Takashima, M Harbers, WH Tham, J Healer, CE Chitnis, W Monteiro, M Lacerda, J Sattabongkot, T Tsuboi, I Mueller
Open Forum Infectious Diseases | OXFORD UNIV PRESS INC | Published : 2021
DOI: 10.1093/ofid/ofab228
Abstract
To achieve malaria elimination, new tools are required to explicitly target Plasmodium vivax. Recently, a novel panel of P. vivax proteins were identified and validated as serological markers for detecting recent exposure to P. vivax within the last 9 months. In order to improve the sensitivity and specificity of these markers, immunoglobulin M (IgM) in addition to immunoglobulin G (IgG) antibody responses were compared with a down-selected panel of 20 P. vivax proteins. IgM was tested using archival plasma samples from observational cohort studies conducted in malaria-endemic regions of Thailand and Brazil. IgM responses to these proteins generally had poorer classification performance than..
View full abstractRelated Projects (2)
Grants
Awarded by National Health and Medical Research Council Australia
Awarded by National Institute of Allergy and Infectious Diseases (NIH)
Awarded by Global Health Innovative Technology Fund
Awarded by Fundacao de Amparo a Pesquisa do Estado do Amazonas-FAPEAM
Awarded by Howard Hughes Medical InstituteWellcome Trust
Funding Acknowledgements
This work was supported by the National Health and Medical Research Council Australia (#1092789, #1134989, and #1043345 to I.M., #1143187 to W.-H.T., and #1173210 to R.J.L.), the National Institute of Allergy and Infectious Diseases (NIH grant 5R01 AI 104822 to J.S.), and the Global Health Innovative Technology Fund (T2015-142 to I.M.). The Brazilian team was partly funded by Fundacao de Amparo a Pesquisa do Estado do Amazonas-FAPEAM (PAPAC 005/2019 and Pro-Estado). M.L. and W.M. are research fellows from CNPq. Additional funding directly supporting field studies was from the TransEPI consortium (supported by the Bill and Melinda Gates Foundation). We also acknowledge support from the National Research Council of Thailand. This work was made possible through Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS. The Walter and Eliza Hall Institute of Medical Research, through the Page Betheras Award to R.J.L., also provided salary support. W.H.T. is a Howard Hughes Medical InstituteWellcome Trust International Research Scholar (208693/Z/17/Z). Part of this work was presented by R.J.L. at the 47th Annual Scientific Meeting of the Australasian Society for Immunology, December 2018, Perth, Australia.